Results of phase I trial of novel herbal therapy for men at high risk of prostate cancer

Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news162233255.html">Results of phase I trial of novel herbal therapy for men at high risk of prostate cancer</a></p> <p>Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer.</p>